# Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

> **NCT05406999** · PHASE2 · RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 900 (estimated)

## Conditions studied

- Neoadjuvant Therapy
- High Risk Prostate Cancer
- Locally Advanced Prostate Cancer
- Intense Endocrine Therapy

## Interventions

- **DRUG:** ADT
- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisolone tablets
- **DRUG:** Enzalutamide
- **DRUG:** Apalutamide
- **DRUG:** Darotamide
- **DRUG:** Rezvilutamide
- **DRUG:** PARP inhibitor
- **PROCEDURE:** Robot-assisted radical prostatectomy

## Key facts

- **NCT ID:** NCT05406999
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2030-06-30
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2022-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05406999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05406999, "Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05406999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*